Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

G1 Therapeutics Inc (NQ: GTHX )

2.699 -0.051 (-1.86%)
Streaming Delayed Price Updated: 10:41 AM EDT, Mar 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 72,887
Open 2.760
Bid (Size) 2.690 (8)
Ask (Size) 2.700 (8)
Prev. Close 2.750
Today's Range 2.690 - 2.790
52wk Range 2.550 - 17.49
Shares Outstanding 42,705,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Analysts Have This to Say About G1 Therapeutics
 
Via Benzinga
Earnings Scheduled For March 1, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million. 
Via Benzinga

Performance

YTD
-52.90%
-52.90%
1 Month
-22.45%
-22.45%
3 Month
-48.00%
-48.00%
6 Month
-79.06%
-79.06%
1 Year
-67.05%
-67.05%

More News

Read More
G1 Therapeutics Provides Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights
From G1 Therapeutics
Via Globe NewsWire
G1 Therapeutics's Earnings Outlook
Via Benzinga
Dow Gains Over 300 Points; S&P 500 Up 1%
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial
Via Benzinga
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Nasdaq Rises 1.5%; G1 Therapeutics Shares Plummet
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
Via Benzinga
US Stocks Open Higher; Dow Jumps 200 Points
Via Benzinga
Why Is Monday.com (MNDY) Stock Up 11% Today?
Via InvestorPlace
NVAX Stock Alert: Novavax Will Provide 1.5 Million More Covid-19 Vaccine Doses to U.S.
Via InvestorPlace
Why Is Sorrento Therapeutics (SRNE) Stock Down 40% Today?
Via InvestorPlace
Why Is G1 Therapeutics (GTHX) Stock Down 52% Today?
Via InvestorPlace
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Via InvestorPlace
G1 Therapeutics Shelves Pivotal Colorectal Trial, After Trilaciclib Triplet Therapy Favored Placebo Arm
Via Benzinga
G1 Therapeutics Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with FOLFOXIRI + Bevacizumab for Metastatic Colorectal Cancer (CRC) (PRESERVE 1)
From G1 Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
Via Benzinga
G1 Therapeutics Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib
From G1 Therapeutics
Via Globe NewsWire
Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer Show that a Single Dose of Trilaciclib Favorably Alters the Tumor Microenvironment
From G1 Therapeutics
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
Via Benzinga
Big Developments Set to be Unveiled at This Year’s San Antonio Breast Cancer Symposium (SABCS)
Via FinancialNewsMedia
G1 Therapeutics Announces Closing of Offering of Common Stock
From G1 Therapeutics
Via Globe NewsWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.